Skip to content

Endocrine Regulation of Lipolysis in Obesity and Diabetes

Atrial Natriuretic Peptide (ANP)-Induced Lipid Mobilization Regulation in Different Adipose Tissue Depots of Obese Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02598544
Acronym
ERLO
Enrollment
55
Registered
2015-11-06
Start date
2013-05-31
Completion date
2015-04-30
Last updated
2016-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Obesity

Brief summary

Adipose tissue (AT) dysfunction is a commonly observed feature of metabolic dysfunction in obesity and diabetes. An important characteristic when examining AT function is the capacity to break down stored lipids (i.e. lipolysis) and its regulation. In the present study, the aim was to investigate whether atrial natriuretic peptide-mediated lipolysis is altered in different adipose tissue depots (subcutaneous and visceral adipose tissue) of obese subjects with or without type 2 diabetes, compared to age-matched lean men. Eventually, the knowledge gained from this research will contribute to a better understanding of the present adipose tissue dysfunction and to the optimization of exercise programs for people with obesity and diabetes.

Interventions

adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination

Sponsors

Jessa Hospital
CollaboratorOTHER
Hasselt University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Lean group: BMI \< 25 kg/m², insulin sensitive (HOMA-Insuline Resistance (IR) \< 2.3), age 40-65 * Obese groups: BMI \> 30 kg/m², presence or absence of type 2 diabetes based on use of glucose lowering medication or HbA1c \> 6.5%, age 40-65

Exclusion criteria

* presence of a history of heart, lung or kidney disease and/or presence of endocrine anomalies. Use of beta-blockade medication.

Design outcomes

Primary

MeasureTime frameDescription
Glycerol release by mature adipocytes, isolated from subcutaneous and visceral adipose tissue, upon stimulation with isoprenalin or ANP (ex vivo)day 1Investigation of concentration effect of ISO/ANP on lipolysis (glycerol release) by mature adipocytes isolated from adipose tissue biopsies, glycerol release is measured in the incubation medium following a 3 hour incubation period. Measured for adipose tissue (subcutaneous and visceral adipose tissue) of both lean and obese subjects
ANP receptor expression profiles on mRNA and protein level in both adipose tissue depots for both lean and obese subjects.day 1Receptor expression determination in order to clarify the underlying mechanism responsible for possible differences in lipolytic responses.
Adipose tissue inflammationday 1Adipose tissue inflammation (by means of FACS analysis) and its relation to insulin sensitivity and adipose tissue function in lean, obese and obese diabetics subjects.

Secondary

MeasureTime frameDescription
weight (kg)day 1
hip circumference (cm)Day 1
waist (cm)Day 1
blood glucoseday 1
blood insulineday 1
Body compositionday 1Body composition (body fath percentage), measured by BIA
blood triglyceridesday 1
blood glycated hemoglobinday 1
blood ANPday 1fasting blood sample to determine blood glucose, insulin, FFA, , glycated hemoglobin and ANP
blood pressure (mmHg)Day 1
Concomitant medicationDay 1
blood FFAday 1
BMI (kg/m²)day 1
body height (m)day 1

Countries

Belgium, Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026